Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

• Published in: Blood 2019-08, Vol.134 (9), p.761-764
• Main Authors: Freeman, Ciara L., Kridel, Robert, Moccia, Alden A., Savage, Kerry J., Villa, Diego R., Scott, David W., Gerrie, Alina S., Ferguson, David, Cafferty, Fergus, Slack, Graham W., Farinha, Pedro, Skinnider, Brian, Connors, Joseph M., Sehn, Laurie H.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Bendamustine Hydrochloride - therapeutic use; Disease Progression; Female; Humans; Lymphoma, Follicular - drug therapy; Lymphoma, Follicular - pathology; Male; Middle Aged; Retrospective Studies; Rituximab - therapeutic use; Young Adult
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.2019000258

Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known about the risk of early progression or incidence of histological transformation. We performed a retrospective analysis of a population-based cohort of 296 patients with advanced-stage FL treated with frontline BR and maintenance rituximab. As previously demonstrated, outcomes with this regimen are excellent, with 2-year event-free survival estimated at 85% (95% confidence interval [95% CI], 80-89) and 2-year overall survival 92% (95% CI, 88-95). Progression of disease within 24 months (POD24) occurred in 13% of patients and was associated with a significantly inferior outcome with 2-year overall survival of 38% (95% CI, 20-55). The only significant risk factor for POD24 at baseline was elevated lactate dehydrogenase (P < .001). Importantly, the majority of POD24 patients (76%) had transformed disease. Compared with a historical cohort treated with rituximab, cyclophosphamide, vincristine, and prednisone, event-free survival has improved and the risk of POD24 has decreased, but a higher proportion of patients with POD24 harbor transformation. The overall incidence of transformation appears unchanged. The presence of occult or early transformation is the main driver of POD24 in FL patients treated with frontline BR. Identification of biomarkers and improved management strategies for transformation will be crucial to improving outcomes. •Frontline bendamustine and rituximab in advanced stage FL has marked efficacy in this population-based analysis.•Early progression within 24 months is associated with poor outcome after BR; however, the majority of patients have transformed lymphoma. [Display omitted]